Navigation Links
Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
Date:3/31/2009

d retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; and any other factors referenced in our other filings with the Securities and Exchange Commission ("SEC") and applicable Canadian regulatory authorities. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicate
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BURLINGTON, Mass. , Dec. 19, 2014 ... biomaterial market will grow at a 12 percent compound ... a result of the aging population and the increasing ... Latin America will also spur demand ... results of dental implant and periodontal treatments. ...
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel drug ... Eye Institute (NEI) at the National Institutes of Health ... to develop a drug-eluting intraocular lens (IOL) for cataract ... vision loss in people over age 40 and the ... Mandell, LayerBio’s Founder and CEO, "There is a critical ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 In contrast ... of LEDs with various colors, Valoya uses proprietary LED ... This offers best possible uniformity which is critical in ... and high spectral accuracy throughout its lifetime which is ... LED tubes. , "The investment cost was clearly ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that Lionel Goldfrank ... succeed Donald Fresne ; Mr. Fresne has also resigned ... of the Board.  In recognition of the many contributions and ... twenty years, the Board designated Mr. Fresne as Chairman Emeritus. ... Search Committee to find a suitable replacement with Biotech industry ...
Breaking Biology Technology:Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... Calif., March 18 Ingenuity Systems, the,leading ... researchers, has,announced that they have extended and ... access to Ingenuity Pathways Analysis,(IPA) software. The ... access to researchers for rapid assessment of ...
... Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTAX) management will present at the 7th ... in the Bay Auditorium of the Bell Harbor Conference Center., The presentation ... The webcast can be accessed at, http://www.celltherapeutics.com ., ... WBBA Invest Northwest Conference ...
... Nadrian Seeman has received the American Chemical Societys Nicholas ... structural DNA nanotechnology. Created in 1902, the Nichols Medal ... and is given by the societys New York section. ... of Chemistry at NYU, founded and developed the field ...
Cached Biology Technology:Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline 2
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... College Park, MD (June 17, 2010) -- An understanding ... essential in fields as diverse as drug delivery, cellular ... the soil. When a driving force is applied, displacement ... in the Journal of Chemical Physics , which ...
... that alcohol use in pregnancy can lead to children ... study fetal alcohol syndrome (FAS) have not made definitive ... effectively treating it, say researchers from Georgetown University Medical ... Neuroscience , four first-year medical students at Georgetown ...
... the important role that a key protein plays in ... greater understanding of stem cells. Timothy L. Megraw, ... outlined his findings in the cover story of the ... article, "CDK5RAP2 Regulates Centriole Engagement and Cohesion in Mice," ...
Cached Biology News:Little is understood about alcohol's effect on fetal development, Georgetown researchers say 2Little is understood about alcohol's effect on fetal development, Georgetown researchers say 3Florida State researcher uncovers protein's role in cell division 2
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
Biology Products: